BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barendregt AM, Veldkamp SR, Hissink Muller PCE, van de Geer A, Aarts C, van Gulik EC, Schilham MW, Kessel C, Keizer MP, Hemke R, Nassar-Sheikh Rashid A, Dolman KM, Schonenberg-Meinema D, Ten Cate R, van den Berg JM, Maas M, Kuijpers TW. MRP8/14 and neutrophil elastase for predicting treatment response and occurrence of flare in patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 2020;59:2392-401. [PMID: 31904851 DOI: 10.1093/rheumatology/kez590] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Keskitalo PL, Kangas SM, Sard S, Pokka T, Glumoff V, Kulmala P, Vähäsalo P. Myeloid-related protein 8/14 in plasma and serum in patients with new-onset juvenile idiopathic arthritis in real-world setting in a single center. Pediatr Rheumatol Online J 2022;20:42. [PMID: 35710418 DOI: 10.1186/s12969-022-00701-x] [Reference Citation Analysis]
2 La C, Lê PQ, Ferster A, Goffin L, Spruyt D, Lauwerys B, Durez P, Boulanger C, Sokolova T, Rasschaert J, Badot V. Serum calprotectin (S100A8/A9): a promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritis. RMD Open 2021;7:e001646. [PMID: 34108235 DOI: 10.1136/rmdopen-2021-001646] [Reference Citation Analysis]
3 Backlund M, Venge P, Berntson L. A cross-sectional cohort study of the activity and turnover of neutrophil granulocytes in juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2021;19:102. [PMID: 34193192 DOI: 10.1186/s12969-021-00600-7] [Reference Citation Analysis]
4 Choida V, Hall-Craggs M, Jebson BR, Fisher C, Leandro M, Wedderburn LR, Ciurtin C. Biomarkers of Response to Biologic Therapy in Juvenile Idiopathic Arthritis. Front Pharmacol 2020;11:635823. [PMID: 33603671 DOI: 10.3389/fphar.2020.635823] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Wei K, Jiang P, Zhao J, Jin Y, Zhang R, Chang C, Xu L, Xu L, Shi Y, Guo S, He D. Biomarkers to Predict DMARDs Efficacy and Adverse Effect in Rheumatoid Arthritis. Front Immunol 2022;13:865267. [PMID: 35418971 DOI: 10.3389/fimmu.2022.865267] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Klein-Wieringa IR, Brinkman DMC, Ten Cate R, Hissink Muller PCE. Update on the treatment of nonsystemic juvenile idiopathic arthritis including treatment-to-target: is (drug-free) inactive disease already possible? Curr Opin Rheumatol 2020;32:403-13. [PMID: 32657803 DOI: 10.1097/BOR.0000000000000727] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Altobelli E, Angeletti PM, Petrocelli R, Lapergola G, Farello G, Cannataro G, Breda L. Serum Calprotectin a Potential Biomarker in Juvenile Idiopathic Arthritis: A Meta-Analysis. J Clin Med 2021;10:4861. [PMID: 34768386 DOI: 10.3390/jcm10214861] [Reference Citation Analysis]